Loading...
Loading...
BOLT| Name | Value |
|---|---|
| Revenues | 5.3M |
| Cost of Revenue | 0.5M |
| Gross Profit | 4.8M |
| Operating Expense | 21.9M |
| Operating I/L | -17.1M |
| Other Income/Expense | 6.3M |
| Interest Income | 1.6M |
| Pretax | -10.8M |
| Income Tax Expense | 0.4M |
| Net Income/Loss | -10.8M |
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company's product pipeline includes BDC-1001, a Phase I/II clinical trial drug for HER2-expressing solid tumors; BDC-2034, a program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program designed to repolarize cells in the tumor microenvironment. Additionally, the company is developing a programmed cell death-ligand 1 program for nonresponsive tumors. These innovative therapies demonstrate Bolt Biotherapeutics' commitment to advancing cancer treatment through targeted immunotherapies.
